Need for exchange transfusion · term and preterm neonates with hyperbilirubinaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Bilirubin‐induced neurological damage (BIND) · term and preterm neonates with hyperbilirubinaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Sudden infant death syndrome · term and preterm neonates with hyperbilirubinaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression‐free survival · advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer
ALK inhibitor leads to lower progression‐free survival: all participants compared with any cytotoxic chemotherapy (high certainty).
1 finding from 1 review
Progression‐free survival in people with central nervous system disease · advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer
ALK inhibitor leads to lower progression‐free survival in people with central nervous system… compared with any cytotoxic chemotherapy (high certainty).
1 finding from 1 review
Overall adverse events · advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer
ALK inhibitor showed no clear difference in overall adverse events compared with any cytotoxic chemotherapy (low certainty).
1 finding from 1 review
Grade 5 adverse events (excluding progressive disease) · advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer
ALK inhibitor showed no clear difference in grade 5 adverse events (excluding progressive disease) compared with any cytotoxic chemotherapy (low certainty).
1 finding from 1 review
Overall survival · advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer
ALK inhibitor leads to lower overall survival compared with any cytotoxic chemotherapy (high certainty).
1 finding from 1 review
Overall response rate · advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer
ALK inhibitor probably leads to higher overall response rate compared with any cytotoxic chemotherapy (moderate certainty).
1 finding from 1 review
Health‐related quality of life: time to deterioration in composite endpoint (cough, dyspnoea, and chest pain) · advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer
ALK inhibitor leads to lower health‐related quality of life: time to deterioration in composite… compared with any cytotoxic chemotherapy (high certainty).
1 finding from 1 review
Success rate at 1 year · Patients needing retrograde filling in root canal therapy (orthograde root canal filling or retreatment not possible; periapical surgery…
It is very uncertain whether super ethoxybenzoic acid (Super-EBA) changes success rate at 1 year compared with intermediate restorative material (IRM) (very low certainty).
1 finding from 1 review
RR 0.90 [0.80, 1.01]
1 study
Very low
Success rate at 1 year · Patients needing retrograde filling in root canal therapy (orthograde root canal filling or retreatment not possible; periapical surgery…
It is very uncertain whether dentine-bonded resin composite changes success rate at 1 year (root as unit, per-protocol analysis) compared with glass ionomer cement (very low certainty).
2 findings from 1 review
Success rate at 1 year · Patients needing retrograde filling in root canal therapy (orthograde root canal filling or retreatment not possible; periapical surgery…
It is very uncertain whether glass ionomer cement changes success rate at 1 year compared with amalgam (very low certainty).
1 finding from 1 review
RR 0.98 [0.86, 1.12]
1 study
Very low
Adverse events · Patients needing retrograde filling in root canal therapy (orthograde root canal filling or retreatment not possible; periapical surgery…
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events · Patients needing retrograde filling in root canal therapy (orthograde root canal filling or retreatment not possible; periapical surgery…
The review found no eligible studies for this question.
1 finding from 1 review
Treatment success rate · Patients needing retrograde filling in root canal therapy (orthograde root canal filling or retreatment not possible; periapical surgery…
Mineral trioxide aggregate (MTA) showed no clear difference in success rate at 4 years compared with super ethoxybenzoic acid (Super-EBA); GRADE not reported.
1 finding from 1 review
RR 1.02 [0.93, 1.12]
1 study
GRADE not reported
Overall success rate · Patients needing retrograde filling in root canal therapy (orthograde root canal filling or retreatment not possible; periapical surgery…
Glass ionomer cement showed no clear difference in success rate at 5 years compared with amalgam; GRADE not reported.
1 finding from 1 review
RR 1.00 [0.84, 1.20]
1 study
GRADE not reported
Success rate at 1 year · Patients needing retrograde filling in root canal therapy (orthograde root canal filling or retreatment not possible; periapical surgery…
It is very uncertain whether mineral trioxide aggregate (MTA) changes success rate at 1 year compared with intermediate restorative material (IRM) (very low certainty).
1 finding from 1 review
RR 1.09 [0.97, 1.22]
2 studies
Very low
Adverse events · Patients needing retrograde filling in root canal therapy (orthograde root canal filling or retreatment not possible; periapical surgery…
The review found no eligible studies for this question.
1 finding from 1 review
Change in FEV1 % predicted at end of antibiotic course: absolute post‐treatment values · adults and children with cystic fibrosis
Summary of findings: single showed no clear difference in change in FEV1 % predicted at end of antibiotic course: absolute… compared with combination intravenous anti‐pseudomonal antibiotic therapy (low certainty).
1 finding from 1 review